Promotion of Random Flap Neovascularisation in Rats with Diabetes Using Botulinum Toxin Type A Through the HIF-1α/VEGF Pathway

Hong-Jie Yan,1,* Fang-Ming Lin,2,* Jing-Jing Li,1 Hao Qin,1 Yi-He Wang,1 Chuan-Hua You1 1Department of Plastic and Cosmetic Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, People’s Republic of China; 2Department of Vascular Surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, 570100, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuan-Hua You, Department of Plastic and Cosmetic Surgery, The First Affiliated Hospital of Hainan Medical University, No. 31 of Longhua Street, Longhua District, Haikou, 570102, People’s Republic of China, Tel +8615120793168, Fax +86-1083161294, Email [email protected]: This study aimed to investigate the effects of botulinum toxin type A (BoTA) on the neovascularisation of diabetic flaps through the factor-1alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway.Methods: A total of 60 male Wistar rats (250– 300 g) were randomly divided into 4 groups. Group A consisted of normal rats receiving saline, Group B received BoTA, Group C were diabetic rats treated with saline, and Group D were diabetic rats treated with BoTA. Random-pattern dorsal skin flaps (3× 9 cm) were created, and saline or BoTA was injected at proximal, mid and distal regions. Ten days later, orthotopic flap transplantation was performed. After 7 days, flap survival rate, haematoxylin–eosin (H&E) staining, and the mRNA expression of HIF-1α and VEGF were evaluated.Results: Flap survival area significantly increased in Group B compared to Group A (P < 0.05), and in Group D compared to Group C (P < 0.05). The highest neovascular density was observed in Group B (P < 0.05), while the lowest was in Group C (P < 0.05). No significant difference was found between Groups A and D. Reverse transcription polymerase chain reaction (RT-PCR) showed that HIF-1α and VEGF expression levels were highest in Group B, followed by Groups A, D, and C (P < 0.05).Conclusion: BoTA promotes flap survival and neovascularisation in diabetic rats by enhancing HIF-1α and VEGF expression. These results suggest a potential therapeutic role of BoTA in improving flap outcomes in diabetic patients.Keywords: botulinum toxin type A, flap, diabetes, factor-1alpha

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2025-06-21
Primary Topic
Advanced Power Generation Technologies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Promotion of Random Flap Neovascularisation in Rats with Diabetes Using Botulinum Toxin Type A Through the HIF-1α/VEGF Pathway

Dove Medical Press (Taylor and Francis Group)
Advanced Power Generation Technologies
article

Promotion of Random Flap Neovascularisation in Rats with Diabetes Using Botulinum Toxin Type A Through the HIF-1α/VEGF Pathway

article en

Abstract

Hong-Jie Yan,1,* Fang-Ming Lin,2,* Jing-Jing Li,1 Hao Qin,1 Yi-He Wang,1 Chuan-Hua You1 1Department of Plastic and Cosmetic Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, People’s Republic of China; 2Department of Vascular Surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, 570100, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuan-Hua You, Department of Plastic and Cosmetic Surgery, The First Affiliated Hospital of Hainan Medical University, No. 31 of Longhua Street, Longhua District, Haikou, 570102, People’s Republic of China, Tel +8615120793168, Fax +86-1083161294, Email [email protected]: This study aimed to investigate the effects of botulinum toxin type A (BoTA) on the neovascularisation of diabetic flaps through the factor-1alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway.Methods: A total of 60 male Wistar rats (250– 300 g) were randomly divided into 4 groups. Group A consisted of normal rats receiving saline, Group B received BoTA, Group C were diabetic rats treated with saline, and Group D were diabetic rats treated with BoTA. Random-pattern dorsal skin flaps (3× 9 cm) were created, and saline or BoTA was injected at proximal, mid and distal regions. Ten days later, orthotopic flap transplantation was performed. After 7 days, flap survival rate, haematoxylin–eosin (H&E) staining, and the mRNA expression of HIF-1α and VEGF were evaluated.Results: Flap survival area significantly increased in Group B compared to Group A (P < 0.05), and in Group D compared to Group C (P < 0.05). The highest neovascular density was observed in Group B (P < 0.05), while the lowest was in Group C (P < 0.05). No significant difference was found between Groups A and D. Reverse transcription polymerase chain reaction (RT-PCR) showed that HIF-1α and VEGF expression levels were highest in Group B, followed by Groups A, D, and C (P < 0.05).Conclusion: BoTA promotes flap survival and neovascularisation in diabetic rats by enhancing HIF-1α and VEGF expression. These results suggest a potential therapeutic role of BoTA in improving flap outcomes in diabetic patients.Keywords: botulinum toxin type A, flap, diabetes, factor-1alpha

Dove Medical Press (Taylor and Francis Group)
Good health and well-being
Openalex Percentile: Top 50%
Advanced Power Generation Technologies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Promotion of Random Flap Neovascularisation in Rats with Diabetes Using Botulinum Toxin Type A Through the HIF-1α/VEGF Pathway · Dove Medical Press (Taylor and Francis Group) (2025) | TGRS Research Map | TGRS